James J. /. Obrien - Jan 3, 2023 Form 4 Insider Report for HUMANA INC (HUM)

Role
Director
Signature
James J. O'Brien
Stock symbol
HUM
Transactions as of
Jan 3, 2023
Transactions value $
$0
Form type
4
Date filed
1/4/2023, 11:35 AM
Previous filing
Oct 12, 2022
Next filing
Apr 12, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HUM Humana Common Award $0 +380 +26.87% $0.00 1.79K Jan 3, 2023 See Footnote F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding HUM Restricted Stock Units 28.9K Jan 3, 2023 Humana Common 28.9K Direct F1, F3
holding HUM Restricted Stock Units 737 Jan 3, 2023 Humana Common 737 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Annual Director's fee payable in stock units which have been deferred at the election of the reporting person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1) and the total includes the vested portion that was subsequently deferred for years 2013 and later.
F2 Director's dividend payment reinvested into stock units on vested and deferred stock units, deferred in accordance with the Plan until his resignation of services as a director at which time the deferred dividend stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule16(b)-3(d).
F3 Shares held by revocable trust account (March 2015), on which reporting person is the sole trustee, holding certain shares of Humana Inc. common stock.
F4 Includes 380 restricted stock units pursuant to the annual Director's Fee Program representing a contingent right to receive one share of Humana Inc. common stock exempt under Rule 16b-3(d)(1)&(3) under the Company's 2019 Amended & Restated Plan of which 100% is vesting on 12/31/2023.